Cover Image
市場調查報告書

轉移性乳癌:開發平台分析

Metastatic Breast Cancer - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 229722
出版日期 內容資訊 英文 1096 Pages
訂單完成後即時交付
價格
Back to Top
轉移性乳癌:開發平台分析 Metastatic Breast Cancer - Pipeline Review, H2 2016
出版日期: 2016年12月07日 內容資訊: 英文 1096 Pages
簡介

所謂轉移性乳癌(第四期或進行性)是指癌細胞由乳房的腫瘤轉移到身體其他部位,並持續擴大增殖的狀態。轉移性乳癌的症狀有劇痛、進行性疼痛、或是病態性骨折、患部骨出現紅斑、腫起、黃膽、肝酵素上升、腹痛、食欲不振、噁心、嘔吐等。治療方法包含荷爾蒙療法,化療,放射線治療,外科手術等。

本報告提供轉移性乳癌的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

轉移性乳癌概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:各大學/研究機關

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 未確認階段的產品

開發中的產品:各企業

調查中的產品:各大學/研究機關

開發治療藥的企業

  • AB Science SA
  • AbbVie Inc.
  • Acceleron Pharma, Inc.
  • Acetylon Pharmaceuticals, Inc.
  • Adgero Biopharmaceuticals, Inc.
  • Advaxis, Inc.
  • Advenchen Laboratories, LLC
  • Alteogen Inc.
  • Amarna Therapeutics B.V.
  • Ambrx, Inc.
  • Amgen Inc.
  • Aphios Corporation
  • arGEN-X BV
  • Aslan Pharmaceuticals Pte. Ltd.
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Beta Pharma, Inc.
  • Biocon Limited
  • Bionovis SA
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Campus Technologies Freiburg GmbH 其他

治療藥的評估

  • 單獨療法的情況
  • 聯合治療的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

開發中產品的最新趨勢

暫停的計劃

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8794IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Metastatic Breast Cancer - Pipeline Review, H2 2016, provides an overview of the Metastatic Breast Cancer (Oncology) pipeline landscape.

Metastatic breast cancer (also called Stage IV or Advanced) is a stage of breast cancer in which cancer cells break away from the tumor in the breast, spread to other parts of the body and keep growing. Symptoms of metastatic breast cancer includes severe, progressive pain, and, less commonly, pathological fracture, erythema over the affected bone, swelling, jaundice, elevated liver enzymes, abdominal pain, loss of appetite, nausea, and vomiting. Other symptoms include fatigue, malaise and weight loss. Treatment includes hormone therapy, chemotherapy, radiation therapy and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Metastatic Breast Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Metastatic Breast Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Metastatic Breast Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Metastatic Breast Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 8, 33, 81, 52, 2, 52, 7 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 4, 7, 7 and 1 molecules, respectively.Metastatic Breast Cancer.

Metastatic Breast Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Metastatic Breast Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Metastatic Breast Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Metastatic Breast Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Metastatic Breast Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Metastatic Breast Cancer (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Metastatic Breast Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Metastatic Breast Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents 2
  • Introduction 9
  • Metastatic Breast Cancer Overview 10
  • Therapeutics Development 11
  • Metastatic Breast Cancer - Therapeutics under Development by Companies 13
  • Metastatic Breast Cancer - Therapeutics under Investigation by Universities/Institutes 23
  • Metastatic Breast Cancer - Pipeline Products Glance 24
  • Metastatic Breast Cancer - Products under Development by Companies 28
  • Metastatic Breast Cancer - Products under Investigation by Universities/Institutes 45
  • Metastatic Breast Cancer - Companies Involved in Therapeutics Development 46
  • Metastatic Breast Cancer - Therapeutics Assessment 185
  • Drug Profiles 220
  • Metastatic Breast Cancer - Dormant Projects 1033
  • Metastatic Breast Cancer - Discontinued Products 1049
  • Metastatic Breast Cancer - Product Development Milestones 1055
  • Appendix 1068

List of Tables

  • Number of Products under Development for Metastatic Breast Cancer, H2 2016 38
  • Number of Products under Development for Metastatic Breast Cancer - Comparative Analysis, H2 2016 39
  • Number of Products under Development by Companies, H2 2016 40
  • Number of Products under Development by Companies, H2 2016 (Contd..1) 41
  • Number of Products under Development by Companies, H2 2016 (Contd..2) 42
  • Number of Products under Development by Companies, H2 2016 (Contd..3) 43
  • Number of Products under Development by Companies, H2 2016 (Contd..4) 44
  • Number of Products under Development by Companies, H2 2016 (Contd..5) 45
  • Number of Products under Development by Companies, H2 2016 (Contd..6) 46
  • Number of Products under Development by Companies, H2 2016 (Contd..7) 47
  • Number of Products under Development by Companies, H2 2016 (Contd..8) 48
  • Number of Products under Development by Companies, H2 2016 (Contd..9) 49
  • Number of Products under Investigation by Universities/Institutes, H2 2016 50
  • Comparative Analysis by Late Stage Development, H2 2016 51
  • Comparative Analysis by Clinical Stage Development, H2 2016 52
  • Comparative Analysis by Early Stage Development, H2 2016 53
  • Comparative Analysis by Unknown Stage Development, H2 2016 54
  • Products under Development by Companies, H2 2016 55
  • Products under Development by Companies, H2 2016 (Contd..1) 56
  • Products under Development by Companies, H2 2016 (Contd..2) 57
  • Products under Development by Companies, H2 2016 (Contd..3) 58
  • Products under Development by Companies, H2 2016 (Contd..4) 59
  • Products under Development by Companies, H2 2016 (Contd..5) 60
  • Products under Development by Companies, H2 2016 (Contd..6) 61
  • Products under Development by Companies, H2 2016 (Contd..7) 62
  • Products under Development by Companies, H2 2016 (Contd..8) 63
  • Products under Development by Companies, H2 2016 (Contd..9) 64
  • Products under Development by Companies, H2 2016 (Contd..10) 65
  • Products under Development by Companies, H2 2016 (Contd..11) 66
  • Products under Development by Companies, H2 2016 (Contd..12) 67
  • Products under Development by Companies, H2 2016 (Contd..13) 68
  • Products under Development by Companies, H2 2016 (Contd..14) 69
  • Products under Development by Companies, H2 2016 (Contd..15) 70
  • Products under Development by Companies, H2 2016 (Contd..16) 71
  • Products under Investigation by Universities/Institutes, H2 2016 72
  • Metastatic Breast Cancer - Pipeline by 3SBio Inc, H2 2016 73
  • Metastatic Breast Cancer - Pipeline by AB Science SA, H2 2016 74
  • Metastatic Breast Cancer - Pipeline by AbbVie Inc, H2 2016 75
  • Metastatic Breast Cancer - Pipeline by Acceleron Pharma Inc, H2 2016 76
  • Metastatic Breast Cancer - Pipeline by Acetylon Pharmaceuticals Inc, H2 2016 77
  • Metastatic Breast Cancer - Pipeline by Adgero Biopharmaceuticals Inc, H2 2016 78
  • Metastatic Breast Cancer - Pipeline by Advaxis Inc, H2 2016 79
  • Metastatic Breast Cancer - Pipeline by Advenchen Laboratories LLC, H2 2016 80
  • Metastatic Breast Cancer - Pipeline by Alteogen Inc, H2 2016 81
  • Metastatic Breast Cancer - Pipeline by Amarna Therapeutics BV, H2 2016 82
  • Metastatic Breast Cancer - Pipeline by Ambrx Inc, H2 2016 83
  • Metastatic Breast Cancer - Pipeline by Amgen Inc, H2 2016 84
  • Metastatic Breast Cancer - Pipeline by Aphios Corp, H2 2016 85
  • Metastatic Breast Cancer - Pipeline by Arvinas Inc, H2 2016 86
  • Metastatic Breast Cancer - Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2016 87
  • Metastatic Breast Cancer - Pipeline by Astellas Pharma Inc, H2 2016 88
  • Metastatic Breast Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2016 89
  • Metastatic Breast Cancer - Pipeline by AstraZeneca Plc, H2 2016 90
  • Metastatic Breast Cancer - Pipeline by Bayer AG, H2 2016 91
  • Metastatic Breast Cancer - Pipeline by Beta Pharma Inc, H2 2016 92
  • Metastatic Breast Cancer - Pipeline by Biocon Ltd, H2 2016 93
  • Metastatic Breast Cancer - Pipeline by Bionovis SA, H2 2016 94
  • Metastatic Breast Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016 95
  • Metastatic Breast Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2016 96
  • Metastatic Breast Cancer - Pipeline by Cantex Pharmaceuticals Inc, H2 2016 97
  • Metastatic Breast Cancer - Pipeline by Cascadian Therapeutics Inc, H2 2016 98
  • Metastatic Breast Cancer - Pipeline by CASI Pharmaceuticals Inc, H2 2016 99
  • Metastatic Breast Cancer - Pipeline by Celgene Corp, H2 2016 100
  • Metastatic Breast Cancer - Pipeline by Celldex Therapeutics Inc, H2 2016 101
  • Metastatic Breast Cancer - Pipeline by Cellectar Biosciences Inc, H2 2016 102
  • Metastatic Breast Cancer - Pipeline by Celltrion Inc, H2 2016 103
  • Metastatic Breast Cancer - Pipeline by Clovis Oncology Inc, H2 2016 104
  • Metastatic Breast Cancer - Pipeline by Corcept Therapeutics Inc, H2 2016 105
  • Metastatic Breast Cancer - Pipeline by CSPC Pharmaceutical Group Limited, H2 2016 106
  • Metastatic Breast Cancer - Pipeline by Curadis GmbH, H2 2016 107
  • Metastatic Breast Cancer - Pipeline by Curaxys SL, H2 2016 108
  • Metastatic Breast Cancer - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 109
  • Metastatic Breast Cancer - Pipeline by Deciphera Pharmaceuticals LLC, H2 2016 110
  • Metastatic Breast Cancer - Pipeline by DexTech Medical AB, H2 2016 111
  • Metastatic Breast Cancer - Pipeline by Dompe Farmaceutici SpA, H2 2016 112
  • Metastatic Breast Cancer - Pipeline by Dr. Reddy's Laboratories Ltd, H2 2016 113
  • Metastatic Breast Cancer - Pipeline by EirGenix Inc, H2 2016 114
  • Metastatic Breast Cancer - Pipeline by Eisai Co Ltd, H2 2016 115
  • Metastatic Breast Cancer - Pipeline by Eli Lilly and Company, H2 2016 116
  • Metastatic Breast Cancer - Pipeline by Ensol Biosciences Inc, H2 2016 117
  • Metastatic Breast Cancer - Pipeline by EOS Biosciences Inc, H2 2016 118
  • Metastatic Breast Cancer - Pipeline by Epigen Biosciences Inc, H2 2016 119
  • Metastatic Breast Cancer - Pipeline by Etubics Corp, H2 2016 120
  • Metastatic Breast Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 121
  • Metastatic Breast Cancer - Pipeline by FibroGen Inc, H2 2016 122
  • Metastatic Breast Cancer - Pipeline by Gene Techno Science Co Ltd, H2 2016 123
  • Metastatic Breast Cancer - Pipeline by Genelux Corp, H2 2016 124
  • Metastatic Breast Cancer - Pipeline by Genentech Inc, H2 2016 125
  • Metastatic Breast Cancer - Pipeline by Genor BioPharma Co Ltd, H2 2016 126
  • Metastatic Breast Cancer - Pipeline by Gilead Sciences Inc, H2 2016 127
  • Metastatic Breast Cancer - Pipeline by Glycotope GmbH, H2 2016 128
  • Metastatic Breast Cancer - Pipeline by GP Pharm SA, H2 2016 129
  • Metastatic Breast Cancer - Pipeline by GTx Inc, H2 2016 130
  • Metastatic Breast Cancer - Pipeline by Halozyme Therapeutics Inc, H2 2016 131
  • Metastatic Breast Cancer - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2016 132
  • Metastatic Breast Cancer - Pipeline by Hetero Drugs Ltd, H2 2016 133
  • Metastatic Breast Cancer - Pipeline by Humorigin Biotechnology Corp, H2 2016 134
  • Metastatic Breast Cancer - Pipeline by Immune Design Corp, H2 2016 135
  • Metastatic Breast Cancer - Pipeline by Immunomedics Inc, H2 2016 136
  • Metastatic Breast Cancer - Pipeline by Immunophotonics Inc, H2 2016 137
  • Metastatic Breast Cancer - Pipeline by Immupharma Plc, H2 2016 138
  • Metastatic Breast Cancer - Pipeline by Incyte Corp, H2 2016 139
  • Metastatic Breast Cancer - Pipeline by Intas Pharmaceuticals Ltd, H2 2016 140
  • Metastatic Breast Cancer - Pipeline by Ionis Pharmaceuticals Inc, H2 2016 141
  • Metastatic Breast Cancer - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2016 142
  • Metastatic Breast Cancer - Pipeline by Johnson & Johnson, H2 2016 143
  • Metastatic Breast Cancer - Pipeline by Kadmon Corp LLC, H2 2016 144
  • Metastatic Breast Cancer - Pipeline by Kancera AB, H2 2016 145
  • Metastatic Breast Cancer - Pipeline by Karyopharm Therapeutics Inc, H2 2016 146
  • Metastatic Breast Cancer - Pipeline by Laboratoires Pierre Fabre SA, H2 2016 147
  • Metastatic Breast Cancer - Pipeline by Mabion SA, H2 2016 148
  • Metastatic Breast Cancer - Pipeline by MacroGenics Inc, H2 2016 149
  • Metastatic Breast Cancer - Pipeline by MandalMed Inc, H2 2016 150
  • Metastatic Breast Cancer - Pipeline by Meabco A/S, H2 2016 151
  • Metastatic Breast Cancer - Pipeline by MedImmune LLC, H2 2016 152
  • Metastatic Breast Cancer - Pipeline by Medivation Inc, H2 2016 153
  • Metastatic Breast Cancer - Pipeline by Merck & Co Inc, H2 2016 154
  • Metastatic Breast Cancer - Pipeline by Merck KGaA, H2 2016 155
  • Metastatic Breast Cancer - Pipeline by Merrimack Pharmaceuticals Inc, H2 2016 156
  • Metastatic Breast Cancer - Pipeline by Merus NV, H2 2016 157
  • Metastatic Breast Cancer - Pipeline by MetaStat Inc, H2 2016 158
  • Metastatic Breast Cancer - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 159
  • Metastatic Breast Cancer - Pipeline by Morphotek Inc, H2 2016 160
  • Metastatic Breast Cancer - Pipeline by Mycenax Biotech Inc, H2 2016 161
  • Metastatic Breast Cancer - Pipeline by NantKwest Inc, H2 2016 162
  • Metastatic Breast Cancer - Pipeline by Natco Pharma Ltd, H2 2016 163
  • Metastatic Breast Cancer - Pipeline by Nektar Therapeutics, H2 2016 164
  • Metastatic Breast Cancer - Pipeline by Neonc Technologies Inc, H2 2016 165
  • Metastatic Breast Cancer - Pipeline by NewLink Genetics Corp, H2 2016 166
  • Metastatic Breast Cancer - Pipeline by Nippon Kayaku Co Ltd, H2 2016 167
  • Metastatic Breast Cancer - Pipeline by Northwest Biotherapeutics Inc, H2 2016 168
  • Metastatic Breast Cancer - Pipeline by Novartis AG, H2 2016 169
  • Metastatic Breast Cancer - Pipeline by Oasmia Pharmaceutical AB, H2 2016 170
  • Metastatic Breast Cancer - Pipeline by OBI Pharma Inc, H2 2016 171
  • Metastatic Breast Cancer - Pipeline by Oncobiologics Inc, H2 2016 172
  • Metastatic Breast Cancer - Pipeline by Oncolytics Biotech Inc, H2 2016 173
  • Metastatic Breast Cancer - Pipeline by OncoMed Pharmaceuticals Inc, H2 2016 174
  • Metastatic Breast Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016 175
  • Metastatic Breast Cancer - Pipeline by Panacea Pharmaceuticals Inc, H2 2016 176
  • Metastatic Breast Cancer - Pipeline by Paras Biopharmaceuticals Finland Oy, H2 2016 177
  • Metastatic Breast Cancer - Pipeline by Pfizer Inc, H2 2016 178
  • Metastatic Breast Cancer - Pipeline by Pharma Mar SA, H2 2016 179
  • Metastatic Breast Cancer - Pipeline by PIQUR Therapeutics AG, H2 2016 180
  • Metastatic Breast Cancer - Pipeline by Plexxikon Inc, H2 2016 181
  • Metastatic Breast Cancer - Pipeline by Polaris Pharmaceuticals Inc, H2 2016 182
  • Metastatic Breast Cancer - Pipeline by Polyphor Ltd, H2 2016 183
  • Metastatic Breast Cancer - Pipeline by Prescient Therapeutics Ltd, H2 2016 184
  • Metastatic Breast Cancer - Pipeline by Prima BioMed Ltd, H2 2016 185
  • Metastatic Breast Cancer - Pipeline by Puma Biotechnology Inc, H2 2016 186
  • Metastatic Breast Cancer - Pipeline by Radius Health Inc, H2 2016 187
  • Metastatic Breast Cancer - Pipeline by Richter Gedeon Nyrt, H2 2016 188
  • Metastatic Breast Cancer - Pipeline by Samyang Holdings Corp, H2 2016 189
  • Metastatic Breast Cancer - Pipeline by Sanofi, H2 2016 190
  • Metastatic Breast Cancer - Pipeline by Seattle Genetics Inc, H2 2016 191
  • Metastatic Breast Cancer - Pipeline by Shanghai Henlius Biotech Co Ltd, H2 2016 192
  • Metastatic Breast Cancer - Pipeline by Sorrento Therapeutics Inc, H2 2016 193
  • Metastatic Breast Cancer - Pipeline by Starpharma Holdings Ltd, H2 2016 194
  • Metastatic Breast Cancer - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2016 195
  • Metastatic Breast Cancer - Pipeline by SynCore Biotechnology Co Ltd, H2 2016 196
  • Metastatic Breast Cancer - Pipeline by Syndax Pharmaceuticals Inc, H2 2016 197
  • Metastatic Breast Cancer - Pipeline by Synthon Holdings BV, H2 2016 198
  • Metastatic Breast Cancer - Pipeline by Taiho Pharmaceutical Co Ltd, H2 2016 199
  • Metastatic Breast Cancer - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016 200
  • Metastatic Breast Cancer - Pipeline by Tocagen Inc, H2 2016 201
  • Metastatic Breast Cancer - Pipeline by Transgene Biotek Ltd, H2 2016 202
  • Metastatic Breast Cancer - Pipeline by Tyme Technologies Inc, H2 2016 203
  • Metastatic Breast Cancer - Pipeline by Vaxil Bio Therapeutics Ltd, H2 2016 204
  • Metastatic Breast Cancer - Pipeline by Vertex Pharmaceuticals Inc, H2 2016 205
  • Metastatic Breast Cancer - Pipeline by VioQuest Pharmaceuticals Inc, H2 2016 206
  • Metastatic Breast Cancer - Pipeline by Vyriad Inc, H2 2016 207
  • Metastatic Breast Cancer - Pipeline by Wilex AG, H2 2016 208
  • Metastatic Breast Cancer - Pipeline by WntResearch AB, H2 2016 209
  • Metastatic Breast Cancer - Pipeline by ZIOPHARM Oncology Inc, H2 2016 210
  • Metastatic Breast Cancer - Pipeline by Zymeworks Inc, H2 2016 211
  • Assessment by Monotherapy Products, H2 2016 212
  • Assessment by Combination Products, H2 2016 213
  • Number of Products by Stage and Target, H2 2016 215
  • Number of Products by Stage and Mechanism of Action, H2 2016 229
  • Number of Products by Stage and Route of Administration, H2 2016 244
  • Number of Products by Stage and Molecule Type, H2 2016 246
  • Metastatic Breast Cancer - Dormant Projects, H2 2016 1060
  • Metastatic Breast Cancer - Dormant Projects (Contd..1), H2 2016 1061
  • Metastatic Breast Cancer - Dormant Projects (Contd..2), H2 2016 1062
  • Metastatic Breast Cancer - Dormant Projects (Contd..3), H2 2016 1063
  • Metastatic Breast Cancer - Dormant Projects (Contd..4), H2 2016 1064
  • Metastatic Breast Cancer - Dormant Projects (Contd..5), H2 2016 1065
  • Metastatic Breast Cancer - Dormant Projects (Contd..6), H2 2016 1066
  • Metastatic Breast Cancer - Dormant Projects (Contd..7), H2 2016 1067
  • Metastatic Breast Cancer - Dormant Projects (Contd..8), H2 2016 1068
  • Metastatic Breast Cancer - Dormant Projects (Contd..9), H2 2016 1069
  • Metastatic Breast Cancer - Dormant Projects (Contd..10), H2 2016 1070
  • Metastatic Breast Cancer - Dormant Projects (Contd..11), H2 2016 1071
  • Metastatic Breast Cancer - Dormant Projects (Contd..12), H2 2016 1072
  • Metastatic Breast Cancer - Dormant Projects (Contd..13), H2 2016 1073
  • Metastatic Breast Cancer - Dormant Projects (Contd..14), H2 2016 1074
  • Metastatic Breast Cancer - Dormant Projects (Contd..15), H2 2016 1075
  • Metastatic Breast Cancer - Discontinued Products, H2 2016 1076
  • Metastatic Breast Cancer - Discontinued Products (Contd..1), H2 2016 1077
  • Metastatic Breast Cancer - Discontinued Products (Contd..2), H2 2016 1078
  • Metastatic Breast Cancer - Discontinued Products (Contd..3), H2 2016 1079
  • Metastatic Breast Cancer - Discontinued Products (Contd..4), H2 2016 1080
  • Metastatic Breast Cancer - Discontinued Products (Contd..5), H2 2016 1081

List of Figures

  • Number of Products under Development for Metastatic Breast Cancer, H2 2016 38
  • Number of Products under Development for Metastatic Breast Cancer - Comparative Analysis, H2 2016 39
  • Number of Products under Development by Companies, H2 2016 40
  • Number of Products under Investigation by Universities/Institutes, H2 2016 50
  • Comparative Analysis by Late Stage Development, H2 2016 51
  • Comparative Analysis by Clinical Stage Development, H2 2016 52
  • Comparative Analysis by Early Stage Products, H2 2016 53
  • Assessment by Monotherapy Products, H2 2016 212
  • Assessment by Combination Products, H2 2016 213
  • Number of Products by Top 10 Targets, H2 2016 214
  • Number of Products by Stage and Top 10 Targets, H2 2016 214
  • Number of Products by Top 10 Mechanism of Actions, H2 2016 228
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 228
  • Number of Products by Top 10 Routes of Administration, H2 2016 243
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016 243
  • Number of Products by Top 10 Molecule Types, H2 2016 245
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016 245
Back to Top